Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies

The Lancet Respiratory Medicine

Volumn 3, Issue 3, 2015, Pages 220-234

  Zumla, Alimuddin ^a,e   Chakaya, Jeremiah ^b   Centis, Rosella ^c   D'Ambrosio, Lia ^c   Mwaba, Peter ^e   Bates, Matthew ^e   Kapata, Nathan ^f   Nyirenda, Thomas ^d   Chanda, Duncan ^e   Mfinanga, Sayoki ^g   Hoelscher, Michael ^h   Maeurer, Markus ⁱ   Migliori, Giovanni Battista ^c  

^a UCL Hospitals NHS Foundation Trust ^*  (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c Care and Research Institute   (Italy)

^d European Developing Countries Clinical Trials Partnership   (South Africa)

^e UNIVERSITY TEACHING HOSPITAL   (Zambia)

^f MINISTRY OF HEALTH   (Zambia)

^g NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIRETROVIRUS AGENT; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DIDANOSINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; STREPTOMYCIN; TENOFOVIR; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IMMUNOLOGICAL ADJUVANT;

ABDOMINAL PAIN; ALLERGY; ANEMIA; ARTHRALGIA; CELL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG REPOSITIONING; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; ENZYME BLOOD LEVEL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEPATITIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPERURICEMIA; ICHTHYOSIS; IMMUNOTHERAPY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LATENT TUBERCULOSIS; LIVER DYSFUNCTION; LUNG RESECTION; MALABSORPTION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NERVE INJURY; NEUROMUSCULAR BLOCKING; NEUROPATHY; NONHUMAN; OPTIC NEURITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RASH; SHORT SURVEY; SIDE EFFECT; SKIN DISCOLORATION; THERAPY DELAY; THERAPY EFFECT; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT DURATION; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VERTIGO; VESTIBULAR DISORDER; VOMITING; WORLD HEALTH ORGANIZATION; CLINICAL PROTOCOL; COINFECTION; COMPLICATION; DRUG COMBINATION; DRUG DEVELOPMENT; HEALTH; HIV INFECTIONS; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADJUVANTS, IMMUNOLOGIC; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CLINICAL PROTOCOLS; COINFECTION; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84924341016     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00063-6     Document Type: Short Survey

References (88)

1. WHO. TB-a global emergency. WHO Press Release 1993: WHO/31.
2. WHO Global Tuberculosis Report 2014 WHO, (accessed Nov 12, 2014). http://www.who.int/tb/publications/global_report/en/.
3. The treatment of tuberculosis: guidelines. Document WHO/HTM/TB/2009.420 2010, WHO, World Health Organization, Geneva. 4th edn.
4. Albanna AS, Smith BM, Cowan D, Menzies D Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J 2013, 42:721-732.
5. WHO Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11 2014, World Health Organization, Geneva, (accessed Feb 18, 2015). http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=, M. Rich, E. Jaramillo (Eds.).
6. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
7. Weiss P, Chen W, Cook VJ, Johnston JC Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis. BMC Infect Dis 2014, 14:333.
8. Heyckendorf J, Olaru ID, Ruhwald M, Lange C Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2014, 190:374-383.
9. Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. Int J Tuberc Lung Dis 2014, 18:147-154.
10. Xu HB, Jiang RH, Li L Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. J Antimicrob Chemother 2011, 66:1687-1695.
11. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 2012, 12:157-166.
12. Pontali E, Matteelli A, D'Ambrosio L, Centis R, Migliori GB Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Rev Anti Infect Ther 2012, 10:1109-1115.
13. Lawn SD, Badri M, Wood R Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005, 19:2109-2116.
14. Gengiah TN, Gray AL, Naidoo K, Karim QA Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 2011, 10:559-574.
15. Decloedt EH, Maartens G, Smith P, Merry C, Bango F, McIlleron H The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS One 2012, 7:e32173.
16. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when co-administered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539.
17. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009, 53:2852-2856.
18. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010, 362:697-706.
19. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011, 365:1492-1501.
20. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011, 365:1471-1481.
21. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011, 365:1482-1491.
22. Manosuthi W, Mankatitham W, Lueangniyomkul A, et al. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study. J Acquir Immune Defic Syndr 2012, 60:377-383.
23. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders (accessed Nov 5, 2014). http://apps.who.int/iris/bitstream/10665/44789/1/9789241503006_eng.pdf?ua=1&ua=1.
24. Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis 2014, 14:563-571.
25. WHO Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01 2015, World health Organization, Geneva, (accessed Nov 4, 2014). http://apps.who.int/iris/bitstream/10665/136471/1/9789241548908_eng.pdf.
26. Vernon A Treatment of latent tuberculosis infection. Semin Respir Crit Care Med 2013, 34:67-86.
27. Fraser A, Paul M, Attamna A, Leibovici L Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2006, 2. CD005435.
28. Cox E, Laessig K FDA approval of bedaquiline-the benefit-risk balance for drug-resistant tuberculosis. N Engl J Med 2014, 371:689-691.
29. Interim guidance on the use of bedaquiline to treat MDR-TB WHO, (accessed Jan 20, 2015). http://www.who.int/tb/information_note_delamanid/en/.
30. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
31. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013, 41:1393-1400.
32. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
33. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014, 44:811-815.
34. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014, 371:723-732. the TMC207-C208 Study Group.
35. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405.
36. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015, published online Jan 26. 10.1164/rccm.201410-1801OC.
37. Boeree MJ, Diacon AH, Dawson R, et al. A dose ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med 2015, published online Feb 5. 10.1164/rccm.201407-1264OC.
38. Dorman SE, Savic RM, Goldberg S, et al. Tuberculosis Trials Consortium. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 2015, 191:333-343.
39. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014, 371:1599-1608.
40. Jawahar MS1, Banurekha VV, Paramasivan CN, et al. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 2013, 8:e67030.
41. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014, 371:1588-1598.
42. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014, 371:1577-1587.
43. Heinrich N, Dawson R, du Bois J, et al. on behalf of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA).Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 2015, published online Jan 27. 10.1093/jac/dku553.
44. Wallis RS, Dawson R, Friedrich SO Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS One 2014, 9:e94462.
45. Nunn AJ, Rusen I, Van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014, 15:353.
46. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012, 40:1430-1442.
47. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012, 367:1508-1518.
48. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem/clavulanate added to linezolid containing regimens in the treatment of MDR/XDR-TB. Eur Respir J 2013, 41:1386-1392.
49. Alsaad N, van Altena R, Pranger AD, et al. Evaluation of co-trimoxazole in treatment of multidrug-resistant tuberculosis. Eur Respir J 2013, 42:504-512.
50. Merle CS, Sismanidis C, Bah Sow O, et al. A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials 2012, 13:61.
51. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008, 12:128-138.
52. Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori GB Bedaquiline in MDR-/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014, 43:289-292.
53. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. Document WHO/HTM/TB2014.23 2014, WHO, World Health Organization, Geneva, (accessed Dec 23, 2014). http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf?ua=1.
54. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.6 WHO, (accessed December 26, 2014). http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf.
55. Policy Implementation Package for new TB drug introduction. Document WHO/HTM/TB/2014.22 2014, WHO, World Health Organization, Geneva, (accessed Dec 25, 2014). http://www.who.int/tb/PIPnewTBdrugs.pdf.
56. Odone A, Houben RM, White RG, Lönnroth K The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets. Lancet Diabetes Endocrinol 2014, 2:754-764.
57. Lönnroth K, Roglic G, Harries AD Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014, 2:730-739.
58. Marais BJ, Lönnroth K, Lawn SD, et al. Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis 2013, 13:436-448.
59. Myer L, Smith E, Mayosi BM Medical inpatient mortality at Groote Schuur Hospital, Cape Town, South Africa, 2002-09. S Afr Med J 2012, 103:28-31.
60. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J 2008, 98:36-40.
61. Ntsekhe M, Matthews K, Syed FF, et al. Prevalence, hemodynamics, and cytokine profile of effusive-constrictive pericarditis in patients with tuberculous pericardial effusion. PLoS One 2013, 8:e77532.
62. Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM 2003, 96:593-599.
63. Pandie S, Engel ME, Kerbelker ZS, Mayosi BM Mycobacterium w Immunotherapy for treating pulmonary tuberculosis-a systematic review. Curr Pharm Des 2014, published online Sept 5. 10.2174/1381612820666140905150215.
64. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014, 371:1121-1130. the IMPI Trial Investigators.
65. Zumla A, Nahid P, Cole ST Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 2013, 12:388-404.
66. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis-current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012, 205(suppl 2):S228-S240.
67. Parida SK, Axelsson-Robertson R, Rao MV, et al. Totally-drug resistant tuberculosis and adjunct therapies. J Int Med 2014, published online May 8. 10.1111/joim.12264.
68. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis 2013, 208:199-202.
69. Guzman JD, Evangelopoulos D, Gupta A, et al. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open 2013, 3:e002672.
70. Ivanyi J, Zumla A Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment. J Infect Dis 2013, 208:185-188.
71. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013, 58:574-576.
72. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med 2013, 188:600-607.
73. Maiga M, Ammerman NC, Maiga MC, et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J Infect Dis 2013, 208:512-519.
74. Uhlin M, Andersson J, Zumla A, Maeurer M Adjunct immunotherapies for tuberculosis. J Infect Dis 2012, 205(suppl 2):S325-S334.
75. Zumla A, Maeurer M Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs. J Infect Dis 2012, 205(suppl 2):S335-S339.
76. Maiga M, Agarwal N, Ammerman NC, et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS One 2012, 7:e30749.
77. Sajid MS, Iqbal Z, Muhammad G, et al. Effect of ivermectin on the cellular and humoral immune responses of rabbits. Life Sci 2007, 80:1966-1970.
78. Kaufmann SHE, Lange C, Rao M, et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med 2014, 2:301-320.
79. Zumla A, Rao M, Parida SK, et al. Inflammation and tuberculosis: host-directed therapies. J Intern Med 2014, published online April 10. 10.1111/joim.12256.
80. Skrahin A, Ahmed RK, Ferrara G, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014, 2:108-122.
81. Walter J, Ware LB, Matthay MA Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014, 2:1016-1026.
82. Bartosh TJ, Ylöstalo JH, Bazhanov N, Kuhlman J, Prockop DJ Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspase-dependent IL1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1). Stem Cells 2013, 31:2443-2456.
83. Mayer-Barber KD, Andrade BB, Oland SD, et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511:99-103.
84. Prockop SE, Bertoncello I Are clinical trials with mesenchymal stem/progenitor cells too far ahead of the science? Lessons from experimental hematology. Stem Cells 2014, 32:3055-3061.
85. Young PP, Schäfer R Cell-based therapies for cardiac disease: a cellular therapist's perspective. Transfusion 2014, published online Aug 22. 10.1111/trf.12826.
86. Barry CE, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009, 7:845-855.
87. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379:1902-1913.
88. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013, 13:529-539.